Cellevate demonstrates successful scale-up of its Cellevat3d[®] nanofiber microcarriers at Testa Center

LUND, Sweden, October 25, 2024 – Cellevate, an innovative biotech company developing next-generation cell culture systems to revolutionize biomanufacturing, is excited to announce the successful scale-up of its ground-breaking Cellevat3d^® nanofiber microcarriers funded by Vinnova/STUNS Life Science. The study was performed at Testa Center in Uppsala, Sweden, in the 10-liter Xcellerex XDR-10 single-use stirred tank bioreactor (Cytiva).

The nanofiber-based Cellevat3d^® microcarriers represent a potential paradigm shift in bioprocessing. They have up to 60x the surface area of “traditional” carriers, creating a true three-dimensional cell culture environment, significantly increasing viable cell densities and viral vector yields in stirred tank reactors. Cellevate plans to launch Cellevat3d^® nanofiber microcarriers in November 2024.

“Scaling up at Testa Center in 10 L stirred tank bioreactor with our new category of nanofiber-based cell culture systems, while maintaining all the cell culture parameters unchanged from lab scale, is a great achievement. The study also demonstrated the ease of use and ease of implementation in bioreactors and our ability to meet industrial bioprocessing scale up demand. We have now added the last piece of the puzzle in securing the success of the global commercial launch of the world’s first nanofiber-based cell culture systems designed to boost viral vector productivity, in just a few weeks in November 2024 at BIO-Europe in Stockholm,” says Laura Chirica, CEO of Cellevate.

“We’re thrilled to have supported Cellevate in their recent 3-week project at Testa Center, where they utilized our XDR10 bioreactor to scale up mammalian adherent cells. It’s fantastic to see innovative biotech companies like Cellevate leveraging our facilities to push the boundaries of cell culture technology. We’re proud to play a part in fostering advancements that help accelerate novel biotherapies development and production”, says Jesper Hedberg, CEO, Testa Center.

For more information, please contact:

Laura Chirica, PhD

CEO Cellevate

Email: laura.chirica@cellevate.com

About Cellevate

Cellevate is a Swedish biotech company developing proprietary nanofiber technology designed to unlock the next generation cell culture systems for cell and gene therapy and novel vaccines biomanufacturing.

The core nanotechnology, Cellevat3d^® is a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of nanofiber microcarriers – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to an improved biomanufacturing productivity and process economy. Cellevat3d^® nanofiber-based cell culture products are designed as an integrated part of upstream bioprocess solutions, from laboratory to large-scale batch production. Cellevat3d^® nanofiber microcarriers have a commercial launch and sales start in November 2024.  
 

For more information, please visit www.cellevate.com.

About Testa Center

Testa Center is a Swedish non-profit, open access innovation hub for biological production, available for academic researchers, start-ups, SMEs and large industry. Clients go to Testa Center to access the bioproduction environment which includes industry standard, state-of-the-art equipment, infrastructure, and expertise. 

In Testa Center, innovation projects can organically build value through pilot testing for scalability/manufacturability, control or reduce risk before entering a GMP production, gain speed towards market and/or generate large amounts of material for research and development. www.testacenter.com